Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy

Table 1

Phase I clinical studies with lonidamine and DON.

Drug	Number of studies	Number of patients per study	Tumor type	Dose escalation	Recommended dose	References
Lonidamine	3 studies	15, 31, and 24 (70)	Several, advanced	350–400 mg/m^2; 180–520 mg/m^2; 60–360 mg/m^2	450 mg daily, orally	[28–30]
DON	5 studies	26, 26, 25, 21, and 17 (115)	Several, advanced		50 mg/m^2/day 5 in 21- or 28-day cycles; 300 mg/m^2 twice weekly in 21-day cycles; 480 mg/m^2 daily for 3 days in 21-day cycles; 400 mg/m^2 by 24-hour infusion in a single day in 21- or 28-day cycles; 450 mg/m^2 twice a week every 2 weeks	[31–35]